Acute Myocardial Infarction
Conditions
Keywords
Acute Myocardial Infarction, Mortality, Registry, Turkey
Brief summary
There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.
Detailed description
Background: There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey. Methods: TURKMI study, as a nation-wide registry, will be conducted in 50 percutaneous coronary intervention -capable centres selected from each EuroStat NUTS region in Turkey according to their population sampling weight, prioritizing the volume of hospital in each region. All consecutive patients with acute MI admitted to the coronary care units within the 48 hours of symptom onset will be prospectively enrolled during a predefined 2-week period. The first step of the study has cross-sectional design in which baseline information such as symptoms, risk factors, time periods at each step from symptom onset to revascularization, way of arrival to hospital, biochemical analysis and in-hospital management and outcome will be assessed. The second step has a cohort characteristics in which enrolled patients will be followed-up up to 2 years. Follow-up visits will be conducted at 1st, 6th, 12th and 24th months, and predictors and risk of cardiovascular events, and implementation of guidelines will be assessed as secondary outcomes. Conclusion: The national TURKMI registry is expected to provide important information to improve the national policy of the diagnosis, management and outcomes of MI in Turkey
Interventions
OTHERno intervention
no intervention
Sponsors
AstraZeneca
Turkish Society of Cardiology
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. having hospitalized within 48 hours of onset of symptoms of the index event 2. had a final (discharge) diagnosis of acute MI either \[ST elevation MI (STEMI) or non ST elevation (NSTEMI)\] with positive troponin levels, and 3. having signed an Informed Consent. To facilitate consecutive enrolment, all patients hospitalized at each participating site with acute MI will be recruited consecutively during the same 2 consecutive weeks (15 days).
Exclusion criteria
1\. Patients unwilling or unable to consent will be excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants died | from enrollment till to 2 years follow up | all cause of death including cardiovascular death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants developed cardiovascular morbidity | from enrollment till to 2 years follow up | non-fatal MI, stroke, coronary or peripheral revascularization, emergency department visit due to chest pain or dyspnea, hospitalization for heart failure will be assessed at 1st month and then at every 6 month intervals until the second year. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactMERAL KAYIKCIOGLU, Prof
Backup ContactMUSTAFA K EROL, Prof
Outcome results
None listed